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Background: The 4H syndrome (hypomyelination, hypodontia, hypogonadotropic hypogonadism) is a newly
recognized leukodystrophy. The classical form is characterized by the association of hypomyelination, abnormal
dentition, and hypogonadotropic hypogonadism, but the recent identification of two genes (POLR3A and POLR3B)
responsible for the syndrome demonstrates that these three main characteristics can be variably combined among
“Pol-III (polymerase III)-related leukodystrophies.”
Case presentation: We report on the clinical, neuroradiological and endocrinological follow-up of a male affected
by 4H syndrome with confirmed POLR3B mutations (c.1568 T > A/p.V523E variant in exon 15 and the novel
c.1988C > T/p.T663I mutation in exon 19). Spastic-ataxic gait with worsening of motor performance, progressive
moderate intellectual disability and language difficulties were the main neurological findings observed. The first six
years of substantial stability of the clinical and imaging features were followed by additional six years that showed a
progressive worsening of motor, language and learning disabilities in relation to a progression of the cerebellar
involvement. Hypogonadotropic hypogonadism and growth hormone deficiency followed by central
hypocortisolism became part of the patient’s phenotype. Thyroid function resulted unaffected during follow up.
Conclusions: A novel mutation in POLR3B in a patient with an analogue phenotype than those previously
described but with more extensive endocrinological features, including hypogonadotropic hypogonadism, growth
hormone deficiency and hypocortisolism, was described. These findings permit to better define the clinical
spectrum of the disease, to direct specific genetic tests and to tailor clinical management.
Keywords: 4H leukodystrophy, POLR3B gene, Hypomyelination, Hypogonadotropic hypogonadism, Growth
impairment, Panhypopituitarism, Recombinant GHBackground
Leukodystrophy is a heterogeneous group of inherited
neurodegenerative disorders characterized by abnormal
central-nervous-system (CNS) white matter at brain im-
aging [1]. Congenital hypomyelinating disorders are the
largest sub-group of leukodystrophies [2]; among these,
the 4H syndrome (hypomyelination, hypodontia, hypogo-
nadotropic hypogonadism) (HLD7, OMIM 607694 and
HLD8, OMIM 614381) has been recently characterized* Correspondence: r.battini@fsm.unipi.it
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creativecommons.org/publicdomain/zero/1.0/genetically with manifestations of hypomyelination of the
brain and of the peripheral nervous system [1–4], associ-
ated, in the classical form, with abnormal dentition (hypo-
dontia) [5] and hypogonadotropic hypogonadism [1–7].
Two causative genes encoding the largest subunits of
human RNA polymerase III (Pol III) -POLR3A and
POLR3B- have been identified [8, 9] and mutations in
these genes may cause four overlapping hypomyelinating
leukodystrophy phenotypes: 1) tremor-ataxia with
central hypomyelination or TACH; 2) 4H syndrome;
3) leukodystrophy with oligodontia (LO); 4) diffuse cere-
bral hypomyelination with cerebellar atrophy and hypo-
plasia of the corpus callosum (HCAHC) [6–10].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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tients, of whom 43 have mutations in POLR3A gene and
62 in POLR3B gene. Except for French Canadian pa-
tients, affected individuals from European backgrounds
were more likely to have POLR3B mutations than other
populations [9, 11].
Regarding the imaging studies, Takanashi et al. [12],
but also Wolff et al. [11], suggested that the Magnetic
Resonance Imaging (MRI) pattern of hypomyelination
and cerebellar abnormality may be distinct between pa-
tients with POLR3A and 3B mutations. Cerebellar atro-
phy was found almost in all patients with 4H syndrome
[11, 13, 14], but the cerebellar anomalies were more se-
vere in patients with POLR3B while the pattern of hypo-
myelinization was more evident in the MRI of POLR3A
mutated patients [11, 12].
We report on the longitudinal clinical and MRI study
of a new patient with Pol III-related leukodystrophy.
The patient was firstly diagnosed as an undefined hypo-
myelination leukodystrophy and reached the final genet-
ically confirmed diagnosis ten years later, following the
description of POLR3A and POLR3B as disease genes.
Patient’s endocrinological profile in adolescence was
evaluated in order to define the endocrine phenotype of




After obtaining informed consent, genomic DNA was
extracted from peripheral blood following the manufac-
turer’s instructions (Qiagen, Hilden, Germany). The entire
coding sequence and intron–exon boundaries of POLR3A
(NM_007055) and POLR3B (NM_018082) genes were
amplified by PCR using intronic primers designed to flank
coding exons. Amplimers were purified using Exo-SAP
(GE Healthcare) and directly sequenced using BigDye
3.1 chemistry (Applied Biosystems, Foster City, CA,
USA) with an ABI Prism 3130 xl automatic sequencer
(Applied Biosystems). Mutations were confirmed in in-
dependent reactions by sequencing both strands and
segregation analysis of the identified mutations was per-
formed by sequencing the corresponding amplicons in
family members.
Endocrinological methods
Centiles of birth weight and length were calculated ac-
cording to Italian reference standards [15]; postnatal
height was expressed as raw measured values and as
standard deviation scores (SDs) according to Tanner
et al. [16]. Bone age was assessed according to the
method of Greulich and Pyle [17]; mid parental
height (MPH) was calculated using measured parental
heights adjusted for male sex [(father height + motherheight)/2) + 6.5 cm]. Baseline blood samples were ob-
tained in the fasting state between 8.00 and 9.00 a.m.;
GH secretion in response to GHRH (1 μg/kg i.v.) plus
arginine provocative test (0.5 mg/kg/i.v.) was assessed
with sampling at 0, 30, 60, 90, 120 min (normal re-
sponse = GH peak > 20 ng/ml). Serum levels of LH,
FSH, Δ4-androstenedione, testosterone, dihydrotestoster-
one (DHT), cortisol, and ACTH were measured by com-
mercially kits. All serum samples were kept at −80 °C up
till to laboratory assessment. Serum levels of GH and
IGF1 (reference values for prepubertal children 277 ±
93 ng/ml) were determined as previously reported [18].
Neurological examination
At each evaluation a senior neurologist examined the
patient using the Brief Ataxia Rating Scale (BARS). This
instrument was selected as it could be rapidly adminis-
tered during the clinical setting without special appli-
ances or equipment; its feasibility and reliability have
been well documented in ataxic patients [19].
Findings
An Italian boy has been referred to our Department at
age 6 years for evaluation of developmental delay and
because of mild ataxic gait from the beginning of unsup-
ported walking; he was followed overtime until to age
20 years. He was born from an uneventful pregnancy by
dystocic delivery [birth weight g 3300 (−0.43 SDS), birth
length cm 49 (−0.98 SDS), birth head circumference cm
35 (0.22 SDS)]. His motor and mental developmental
milestones were delayed: he was able to walk unsup-
ported at the age of 16 months, however, he was de-
scribed as “clumsy” and unstable; he spoke with
meaningful words at 18 months and brief sentences
at 24 months with following speech word by word.
Dentition was also delayed: front incisor teething was
presented at 4 years and successively normal teeth
progression continued. Attention deficit and mild
learning impairment were also reported since his pri-
mary school attendance.
At the age of 7 years, cerebellum signs as ataxic gait,
mild tremor of upper limb, nystagmus, ocular motor ab-
normalities, such as hypometric saccades, and dysarthric
language were the prominent clinical manifestations.
Brain MRI was characterized by a diffusely hyperin-
tense signal on T2-weighted images of the cerebral white
matter with sparing of optic radiation. The cerebellar
vermis was atrophic (Fig. 1a).
In order to make a differential diagnosis between the
known leukodystrophies, serum levels of aminoacids,
alfa-fetoprotein, carcinoembryonic antigen, lysosomal
enzyme (arilsulfatase, betaesasominidase, betagalactocer-
obrosidase), fitanic and pristanic acid, very-long chain
fatty acids, sialic acid and isoelectric focussing of
Fig. 1 Hypomyelination with cerebellar atrophy: long term follow-up evaluation. a (7 years). b (10 year). c (13 years). d (15 years). e (19 years):
Axial and coronal T2-weighted images show extensive cerebral white matter (WM) abnormalities with predominant involvement of the deep and
subcortical WM; note the sparing of optic radiation (arrows), perirolandic WM and partial splenum corpus callosum. The head arrows (a-e), instead,
indicate small hypointense dot in the posterior limb of the internal capsule. Mild abnormal hyperintensity involves the cerebellar WM. Sagittal T1-
weighted images show a thin corpus callosum and shrunken cerebellar cortex with enlarged fissures. The pons is normal. At age of 13 years MRI
(c) revealed a mildly increased cortical atrophy of cerebellar hemispheres that remained stable in the following MRI exams. No significative
changes were observed during the yrs on WM abnormalies
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normal limits. In addition, molecular genetics ruled out
mutations in PLP1, GJC2/GJA12 and HSPD1.
EEG recording showed mild occipital anomalies that
disappeared with time, showing only a low amplitude ofbackground activity. Serial electrophysiological studies
showed that auditory brain-stem responses (ABR) have
always been normal; upper limb somato-sensory evoked
potential (SSEP) were abnormal but remained stable
with time; nerve velocity conduction showed a sensory
Battini et al. BMC Medical Genetics  (2015) 16:53 Page 4 of 8peripheral delay, while the motor component was nor-
mal. Lower leg motor evoked potentials (MEP) were not
detectable while upper limb stimulation was normal.
Flash visual evoked potentials (F-VEP) and electro-
retinogram (ERG), instead, showed a slow deterioration
with progressive reduced amplitude during the follow-
up, consistently the boy developed low visual acuity.
Neurophysiological studies performed during the
follow-up are shown in Table 1.
Around the age of 10 years intention tremor increased
and at age of 13 years, the boy showed progressive gait
abnormalities due to spasticity associated with ataxia
and slow cognitive regression without discrepancy be-
tween verbal and performance quotient (Total IQ 62)
became clear. Despite the absence of subjective sensory
troubles at lower limbs, the patient showed an electrocli-
nical sensory neuropathy, not reported until now in
other patients [3, 11], even if peripheral nerve hypomye-
lination on electron microscopy in sural nerve biopsy
were already described in three patients, despite their
normal nerve-conduction studies [3] and a mild lack of
myelin was observed also in the nerve biopsy of a pa-
tient of Wolf series [11]. These nerve pathology observa-
tions seem to be in agreement with the findings on
nerve conduction studies of the lower limbs in our
patients.
Comparing to the 7 years brain MRI, the important
cerebral white matter hyperintensity remained substan-
tially stable in the sequential examinations at 10-13-
15 years of age (Fig. 1b, c and d respectively), with the
exception of a worsening in the atrophy of cerebellar
hemispheres that became evident from age 13 years
(Fig. 1c).Table 1 Neurophysiological data of the patient during follow-up
Age EEG ABR SSEP mNCV
Upper Limbs (UL) UL Low
7 years occipital anomalies N N9:8.2 ms N N
N13:9.8 ms
N20:18 ms
13 years ———— N N9: 8.6 ms N N
N13:11.3 ms
N20:19 ms
17 years Low amplitude
background activity
N ——— —— ——
19 years Low amplitude
background activity
N N9: 8.6 ms N N
N13:13.3 ms
N20:2 ms
EEG electroencephalogram, ABR auditory brainstem response, SSEP somatosensitive
F-VEP flash visual evoked potentials, ERG electroretinogramm, MEP motor evoked p
———not done, N normal, n.d not detectableAt 15 years, the coding region and the flanking exon/
intron boundaries of POLR3A and/or POLR3B genes
were amplified and sequenced. Two compound hetero-
zygous missense mutations in POLR3B gene were identi-
fied: the common V523E variant in exon 15 [9, 11],
inherited from his mother and the novel T663I mutation
in exon 19, inherited from his father.
At 19 years, the adolescent presented a clear spastic-
ataxic gait with worsening of motor performance that in-
cluded upper limb functions; he could walk autono-
mously but he needed a wheelchair when walking for
long distances.
His cognitive profile worsened, revealing a moderate
intellectual disability (Total IQ 32), language became
progressively worse and slow and the comprehension of
his speech was increasingly difficult.
Brain MRI showed extensive white matter abnormal-
ities with predominant involvement of the deep and sub-
cortical white matter; the cerebellum was shrunken, with
thin folia and enlarged fissures that were moderately ab-
normal in the hemispheres and severely abnormal in the
vermis (Fig. 1e). Proton single voxel Magnetic Resonance
Spectroscopy (1H MRS) was added to serial MRI follow-
up, acquired from the posterior centrum semiovale
white matter and interhemispheric parieto-occipital gray
matter. MRS evaluations during the follow-up showed a
relative decrease of choline peak, related to the N Acetil
Aspartate and Creatine peaks, involving the white matter
and slightly the gray matter as well, probably related to
the abnormal myelination. These data remained stable
during overtime, as demonstrated when comparing be-
tween the last examination (Fig. 2a and b) and the first
one (Fig. 2c and d).sNCV F-VEP/ERG MEP
er Limbs (LL) UL LL P100 ERG UL LL
N N 141 ms N —— ———
18.7 μV
50 μV 50 μV 145 ms N —— ———
2.8 ms 4.3 ms 11.4 μV
35 m/s 26 m/s
——— ——— 142 ms N N n.d.
−2.8 μV
50 μV 50 μV n.d. N N n.d.
3.1 ms 4.9 ms
37 m/s 28 m/s
evoked potentials, NCV nerve conduction velocity (m: motor; s: sensitive),
otentials
Fig. 2 a-d. Single voxel short TE (35 ms) 1H-MRS acquired from posterior centrum semiovale (WM) and interhemispheric parieto-occipital gray
matter (GM) at 19 years (a-b). Single voxel short TE (35 ms) 1H MRS acquired from posterior centrum semiovale (WM) and interhemispheric
parieto-occipital (GM) at 19 years (a - b); a comparison with the first 1H-MRS acquisition (7 years) was shown (c-d). In WM was present a de-
creased Choline (Cho) that is slightly reduced also in GM; no changes in proton MRS have been observed over the time
Fig. 3 Longitudinal evolution of the disease emerged considering
BARS scores (column) and full-scale IQ at Wechsler scale
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to those reported in patients with POL3B gene muta-
tions with a 4H syndrome, particularly related to the
cerebellar involvement. Our patient showed, in fact, se-
vere hypomyelination from the beginning of the disease
and mild progression of the cerebellar atrophy that was
particularly marked in the vermis [2, 13]. As in the large
series of patients reported [11] the optic radiation (Fig. 1,
arrows) and the dentate nucleus also in our patient were
spared; indeed a small hypointense dot in the posterior
limb of the internal capsule was seen in our patient too
(Fig. 1, head arrows). The last MRI evaluation at 19 years
did not show a significative supratentorial atrophy al-
though the cognitive decline could suggest that feature,
as reported in literature [11].
The disease progression was very slow at the begin-
ning and progressively accelerated both from a clinical
and imaging point of view: in the adolescent age the boy
showed worsening of motor disabilities and language,
particularly of dysarthria and gait disability, and learning
abilities in relation to progression of the cerebellar in-
volvement (Fig. 1a-e).
BARS scale was used to assess the clinical picture and
the score of each BARS test designed the longitudinal
evolution during the follow-up (Fig. 3). Clinical signs of
our patient in association to other outcome measures
(Wechsler scale for intellectual quotient and MRI data)
were considered to show the outcome grading of disease
severity (Fig. 3).
Clinical examination at 19 years showed severe short
stature [height, cm 151.0 (−3.6 SDs); MPH, cm: 168.5(−0.9 SDs)], overweight [kg: 60.5 (weight for height ex-
cess: 47.6 %)], and severe puberty delay [G1, Ph2; mean
testicular volume, ml: 2 (−8.4 SDs)]. Assessment of re-
productive axis was performed and low testosterone
concentrations as well as low values of basal and stimu-
lated LH and FSH were found (Table 2), concluding for
the diagnosis of hypogonadotropic hypogonadism. Due
to height impairment, GH-IGF1 axis was also explored,
showing subnormal GH secretion and low IGF1 values,
permitting the diagnosis of GH deficiency (GHD). The
remaining of the pituitary axis was not affected, but low
normal values of both ACTH and cortisol were found
(Table 2). Reduced bone mineral density (BMD) was
found at both lumbar spine (BMD area: −2.1 SDs; BMD
Table 2 Endocrinological data at the age 19 years
Parameter Baseline 6 month GH therapy Normal values
GH basal, ng/ml 0.3 — —
GH peak, ng/ml 2.0 — >9.1
IGF1, ng/ml 84.6 349.0 127-424
LH basal, UI/L 0.6 — 1.4-12.7
LH peak, UI/L 1.1 — >5
FSH basal, UI/L 1.0 — 1.3 – 19.5
FSH peak, UI/L 1.4 — —
Testosteone, ng/ml <0.1 <01 1.7-7.8
ACTH, pg/ml 14 12 <50
Antimüllerian hormone, ng/ml 30.0 — 1.2-15.0
Cortisol, μg/dla 7.0 0.6 6.7-22.6
TSH, μU/ml 1.9 1.8 0.4-3.4
fT3, pg/ml 4.4 4.0 2.7-5.7
fT4, ng/dl 1.2 1.1 0.7-1.7
aconfirmed in multiple samples in different days and also by reduced values of urinary 24 h cortisol
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SDS; BMD volume −5.0 SDs). Treatment with recom-
binant GH was started (0.25 mg/kg/week), while testos-
terone administration was delayed to improve the severe
growth delay. At 6 and 12 months of GH therapy,
growth velocity increased to 7.7 cm/year and to 6.0 cm/
year; IGF1 levels normalized (Table 2), but overt central
hyposurrenalism was detected after 6 months of GH ad-
ministration (Table 2) and substitutive treatment with
long-acting hydrocortisone (Plenadren®, 20 mg/daily)
was started. Transdermal testosterone (Tostrex®, 10 mg/
daily) was added after 12 months of GH administration.
Thus, hypogonadotropic hypogonadism as a part of
the phenotypic spectrum of 4H syndrome was confirmed
[4, 6, 20, 21]; however, in our patient, pituitary function
resulted more largely affected than usually described, as
suggested by the presence of GHD and hyposurrenalism.
Normal thyroid function was found in the present ado-
lescent as well as in other patients [11].
GHD has been suspected in another young adult pa-
tient, but he showed normal adult stature and dynamic
assessment of GH secretion was not performed [20, 22];
thus, diagnosis relied only on low IGF1 values [20]. We
explored GH status by a potent test because of a nega-
tive impact of adipose tissue on GH secretion [23]. An
other adolescent patient with short stature and partial
GHD has been described [21] and, recently, additional 5
subjects with 4H syndrome and GHD have been re-
ported in the large series of Wolf et al. [11], but endo-
crine data to support the diagnosis have been not shown
[21]. However, only 10 patients were tested for GHD
and the effective number of those with short stature was
not shown in the Wolf ’s series [11].Conversely, normal GH-IGF1 axis has been described
in an adolescent boy with 4H syndrome and growth
delay [6].
In addition, impaired ACTH-cortisol axis developed in
this boy in late adolescence. Start of GH therapy may
have unmasked a latent hypocortisolism as well known
in panhypopituitarism.
Reduced BMD values have been found in the present
patient, determining an increase in fracture risk. This is
an unreported, but not unexpected, finding of the 4H
syndrome, since both GHD and hypogonadism may im-
pair bone health [24, 25]; reduced BMD might be, more-
over, related to the poor physical activity, as reported in
other neurological diseases [26, 27].
Conclusions
We report on longitudinal follow-up of Pol III-related
leukodystrophy in a boy who manifested the combin-
ation of the major clinical findings (hypomyelination,
motor dysfunction, abnormal dentition and hypogonado-
tropic hypogonadism) related to the 4H syndrome [1–7].
The clinical phenotype of our patient shares some fea-
tures with the four overlapping clinical syndromes de-
scribed before the identification of the mutations in
POLR3A and POLR3B genes, confirming that the various
allelic hypomyelinating disorders do not represent dis-
tinct clinical entities but a continuous spectrum. Our pa-
tient with early presentation, so far remains ambulant;
initial ataxic gait has become progressively spastic; he
did not present a true hypodontia but only delayed
eruption of his deciduous teeth and a mild intellectual
disability with slow cognitive regression, a peripheral
neuropathy and multiple pituitary deficiencies associated
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suggesting an intermediate phenotype.
Abnormal smooth pursuit and nystagmus remain the
main ocular features without signs of optic atrophy so
far that have to be investigated during the follow up.
GHD might be a more common finding than usually
considered [11], but the true GH secretory status in pa-
tients with 4H syndrome remains unclear till homoge-
neous and large series of patients will be assessed.
Indeed, GH secretory status should be adequately
assessed when impaired linear growth is present and GH
treatment should be started when GHD was confirmed,
considering the efficacy of the GH therapy also at the
late age of our subject.
Pituitary pathology may be progressive in the 4H syn-
drome and hypophyseal function should be monitored
during lifespan, to warrant an adequate substitutive ther-
apy patients if pituitary abnormalities will develop,
mainly regarding lifesaving therapies as hydrocortisone,
because abnormal adrenal function may be implicated in
the reduced survival rate reported in these patients [11]
in addition to deterioration of neurological functions.
BMD values should be followed during hormonal sub-
stitutive therapies to verify its improvement. Regarding
bone features, mild osteopetrosis has been reported in 3
patients of Wolf ’s series [11], but we did not performed
X-ray examination of the skeleton in this patient.
In addition, adequate follow-up should be done during
substitutive therapies not only regarding the physical
features, but also regarding neurological abnormalities.
In fact, experimental data indicated that both GHD and
testosterone deficiency may be involved in impairing
myelinisation process [28–30].
Our findings expand the clinical spectrum of allelic vari-
ants in “Pol-III-related leukodystrophies” and suggest that
these mutations are probably under diagnosed in congeni-
tal hypomyelinating disorders. For the clinicians, it is im-
portant to observe the additional findings of the syndrome
to optimize long term management. A better definition of
the phenotypic involvement with the aid of a neurophysio-
logic assessment allows a better understanding of func-
tional deficits and helps in the management of this
disorder. In addition, this report supports a progressive
hypophyseal endocrine dysfunction with ageing that
should be highlighted in larger series of patients.
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